通心络胶囊治疗非ST段抬高型急性心肌梗死的效果及对心肌组织灌注水平的影响

目的探讨通心络胶囊治疗非ST段抬高型急性心肌梗死(NSTEMI)的效果及对心肌组织灌注水平的影响。方法 2017年2月-2018年4月我院收治的100例NSTEMI患者,按照随机数表法分为观察组及对照组各50例,对照组给予常规抗心肌缺血治疗及抗凝治疗,观察组在对照组基础上加服通心络胶囊。比较两组临床总有效率、冠状动脉造影TIMI血流分级及并发症情况。结果观察组临床总有效率为88.00%明显高于对照组66.00%(P<0.05);观察组TIMI分级中0级、1级比例较对照组明显减少,2级、3级比例较对照组明显增加(P<0.05);观察组并发症总发生率20.00%与对照组总发生率24.00%差异不显著(P>0.05)。结论应用通心络胶囊治疗NSTEMI能够有效提高患者疗效,改善心肌组织灌注水平,并发症较少。     

Gastrointestinal bleeding as presentation of small bowel metastases of malignant melanoma: Is surgery a good choice?

INTRODUCTIONMelanoma shows a particular predilection in involving small intestine both in a single site and in multiple localization and acute or chronic gastrointestinal bleedings are often the first sign of tumour.PRESENTATION OF CASEWe report two cases of GI metastases of malignant melanoma, one presented with only a big mass that cause intestinal obstruction and the other with a tumour spread throughout the small intestine that produce enterorrhagia.DISCUSSIONDiagnosis and follow-up are very difficult: CT scan, PET-CT scan and capsule endoscopy should be complementary for the assessment of patients with GI symptoms and melanoma history.CONCLUSIONWhat is the role of surgery? Several studies suggest metastasectomy to achieve both R0 results and palliative resolutions of acute symptoms, such as obstruction, pain, and bleeding.     

复方益气润肠胶囊体外抗菌作用研究及对小鼠肠推进的影响

目的:研究复方益气润肠胶囊对肠道常见细菌的体外抗菌作用,及对正常小鼠、便秘小鼠排便和肠推进作用的影响。方法:采用微量稀释法测定复方益气润肠胶囊对多种常见临床致病菌(金黄色葡萄球菌耐甲氧西林株、肺炎克雷伯菌、鼠伤寒沙门菌、蜡样芽孢杆菌、粪肠球菌、藤黄微球菌、铜绿假单胞菌等)的最小抑菌浓度(MIC)值,以评价其体外抗菌活性;通过小鼠肠推进实验观察该胶囊对正常小鼠肠推进率的影响和对便秘模型小鼠首次排黑便时间、6 h排便量及肠推进率的影响。结果:抗菌实验显示,复方益气润肠胶囊体外对金黄色葡萄球菌耐甲氧西林株M1233和肺炎克雷伯菌的MIC均为3.125 mg/mL,对金黄色葡萄球菌耐甲氧西林株M1805、铜绿假单胞菌、蜡样芽孢杆菌、粪肠球菌及藤黄微球菌的MIC均为6.250 mg/mL,对鼠伤寒沙门菌的MIC为25.000 mg/mL。对正常小鼠的肠推进实验显示,复方益气润肠胶囊高、中、低剂量给药组小肠推进率均高于空白组,差异有统计学意义(P<0.05或P<0.01);对便秘模型小鼠的肠推进实验显示,各给药组首次排黑便时间均短于便秘模型组,6 h排便量均大于便秘模型组,小鼠肠推进率均高于便秘模型组,差异有统计学意义(P<0.05或P<0.01)。结论:复方益气润肠胶囊具有理想的体外抗菌效果和较好的肠推进作用。     

The Use of a PEG/Ascorbate Booster Following Standard Bowel Preparation Improves Visualization for Capsule Endoscopy in a Randomized,Controlled Study

Background Background/Aims: The increasing use of capsule endoscopy (CE) to examine the gastrointestinal tract highlights the need to establish intestinal preparations that ensure optimal visualization while maximizing patient adherence. Thus, we assessed whether bowel preparation involving dietary restriction and a booster regimen produces adequate CE visualization in a real-world clinical setting.Methods We conducted a randomized, double-blind, prospective study of CE procedures at 2 tertiary-care centers. Patients were allocated to 3 groups: group 1 followed a clear liquid diet and fasting-based bowel preparation for the exploration (n = 55); group 2 followed the same procedure as group 1 and then ingested 1 L of a polyethylene glycol (PEG)/ascorbic acid booster solution when the capsule reached the small intestine (n = 55); and group 3 followed the same procedure but ingesting only 0.5 L of the booster solution (n = 56). The quality of visualization and the average gastric, orocecal and small-bowel transit times were evaluated.Results A total of 166 patients participated in the study. Significantly higher quality of visualization (Park score) was obtained in group 3 (2.28 ± 0.59) than in group 1 (1.84 ± 0.54, P < .001), while there were no significant differences in the average gastric (range: 36.58-48.32 min, P = .277), orocecal (range: 322.58-289.45 min, P = .072), and small-bowel transit time (range: 280.71-249.95 min, P = .286) between the 3 groups.Conclusions Following a clear liquid diet and fasting-based bowel preparation for CE exploration, administering a booster solution of PEG/ascorbic acid after the capsule had reached the small intestine improves mucosal visualization and cleansing without affecting capsule transit times.     

Experimental models of osteoarthritis: the role of immobilization

Evidence is reviewed from animal experiments supporting the hypothesis that immobilization, for whatever reason, is one of the pathogenetic factors in musculo-skeletal degeneration. It shows beyond reasonable doubt that immobilization is not only a cause of osteoarthritis but that it delays the healing process.     

艾克清胶囊体外抗肿瘤作用的实验研究

目的：观察艾克清胶囊对人肺腺癌细胞（A549）、食管癌细胞（Eca9706）增殖的抑制作用。方法：采用A549细胞及Eca9706细胞为实验对象,用四氮唑（MTT）法检测二者的生存率,用公式计算细胞抑制率,在倒置显微镜下观察二者的细胞形态学改变。结果：①艾克清胶囊能显著抑制A549细胞及Eca9706细胞的增殖,并且有显著的量效关系。②艾克清胶囊低剂量对A549细胞的增殖抑制与对照组相比有一定的抑制作用,但无统计学意义,其对细胞的形态学有一定的影响;在低剂量下,Eca9706细胞增殖速度较快;③艾克清胶囊高剂量能显著影响A549细胞的形态,有直接杀死此两种肿瘤细胞的作用。结论：艾克清胶囊对A549细胞及Eca9706细胞的增殖有明显的抑制作用。抑制机制可能是通过影响细胞的增殖周期或促进了细胞的死亡。     

越鞠胶囊与贯叶连翘抗抑郁作用的对比研究

目的:研究越鞠胶囊、贯叶连翘的抗抑郁作用。方法:采用小鼠悬尾实验、小鼠强迫游泳实验、利血平诱导小鼠体温下降实验和开场实验研究越鞠胶囊、贯叶连翘的抗抑郁作用。结果:在小鼠悬尾实验中,越鞠胶囊大剂量组、贯叶连翘大、中剂量组能明显缩短模型小鼠的不动时间;在小鼠强迫游泳实验中,越鞠胶囊、贯叶连翘各剂量组能明显缩短模型小鼠的不动时间;在利血平诱导的体温下降实验中,越鞠胶囊大剂量组、贯叶连翘大、中剂量组能明显抑制小鼠体温的下降;实验表明贯叶连翘提取物的作用效价强度要大于越鞠胶囊。结论:越鞠胶囊、贯叶连翘有一定的的抗抑郁作用,贯叶连翘提取物的作用效价强度要大于越鞠胶囊。     

益气通络胶囊治疗糖尿病合并冠状动脉粥样硬化性心脏病心绞痛30例

目的观察益气通络胶囊治疗糖尿病合并冠状动脉粥样硬化性心脏病（以下简称冠心病）心绞痛的临床疗效。方法将60例糖尿病合并冠心病心绞痛患者随机分为2组。对照组30例子硝酸异山梨酯片10mg,每日3次1：7服,治疗组30例在对照组基础上加用益气通络胶囊5粒,每日3次口服。2组均1个月为1个疗程。观察2组治疗前后中医证候,心绞痛发作次数、持续时间,心电图,血糖水平。结果①心绞痛治疗组总有效率96．7％,对照组总有效率46．7％,2组比较差异有统计学意义（P〈0．05）,治疗组优于对照组;②中医证候治疗组有效率为90％,对照组有效率为53．33％;2组比较差异有统计学意义（P〈0．05）,治疗组优于对照组;心电图治疗组有效率为86．67％,对照组有效率为50％,2组比较差异有统计学意义（P〈0．05）。结论益气通络胶囊治疗糖尿病合并冠心病心绞痛疗效确切。     

坤泰胶囊对绝经早期妇女生活质量及乳房胀痛、阴道流血的影响

目的 研究中药坤泰胶囊对绝经早期妇女生活质量以及乳腺、阴道流血的影响。 方法 绝经早期妇女104例,其中有子宫者54例,按随机表分为坤泰组和激素组各27例;无子宫者50例,按随机表分为坤泰组和激素组各25例。坤泰组予口服坤泰胶囊4粒,每日2次;激素组予口服倍美力（结合雌激素片,premarin）每日0.45 mg,有子宫者加用安宫黄体酮每日2 mg。治疗时间为1年。每3个月随访1次,受试者每日记录乳房胀痛和阴道流血情况,随访时完成绝经期生活质量量表,用药前后分别行盆腔超声、乳房超声检查及血清雌二醇（E₂）、卵泡刺激素（FSH）测定。 结果 在生活质量方面,除有子宫两组心理状态从用药6个月开始起效外,坤泰组效果与激素组相似,均在治疗3个月起均显著改善了绝经妇女的血管舒缩症状、心理状态和生理状态,组间比较差异无统计学意义。坤泰胶囊对有子宫者性生活的改善从用药后9个月开始起效,无子宫者性生活无改善;激素组有无子宫性生活皆从3个月起效。两组在治疗各时间点的乳房胀痛发生率无明显差别,但在用药1～3个月时有子宫激素组乳房胀痛的程度显著高于有子宫坤泰组。用药1～3个月有子宫坤泰组阴道流血的发生率和累计天数均显著低于激素组,两组用药前后子宫内膜均在正常范围内。坤泰组治疗前后E2、FSH差异无统计学意义;有子宫激素组治疗结束后E₂较治疗前显著升高,FSH显著性降低（P<0.05）。 结论 坤泰胶囊能显著改善绝经早期妇女的生活质量,且引起乳房胀痛与阴道流血的不良反应相对较少,对性激素影响不大。